https://diabetes.acponline.org/archives/2020/11/13/7.htm. A new summary of the guideline from Kidney Disease: Improving Global Outcomes (KDIGO) highlights important points for clinicians, including recommendations about
These findings highlight a key deficiency in the utilization of these newer diabetes drugs and an opportunity for improving the pharmacotherapy of patients with diabetes,” the authors concluded.
Our results highlight the importance of routine screening for kidney disease, particularly in adults with T1D and perhaps especially in those with obesity.” They also called for additional studies on the
Accordingly, the associated BMJ Rapid Recommendations will provide risk stratified recommendations and highlight the need for shared decision making to allow patients and clinicians to make well informed decisions together,” the
Tirzepatide, a not-yet-approved dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, was tested against placebo and semaglutide in recent studies.
The one-step screening process, which used a two-hour fasting glucose tolerance test, found more cases of gestational diabetes in a randomized trial, but perinatal and maternal complications did not differ.
A cohort study found a threefold increase in the risk for diabetic ketoacidosis with sodium-glucose cotransporter-2 (SGLT-2) inhibitors compared to dipeptidyl peptidase-4 (DPP-4) inhibitors, with possible variation by severity or duration of diabetes
A industry-conducted cohort study in Finland found that childhood obesity, hypoglycemia, hyperglycemia, diabetes, and challenges in motor-social development did not appear to be associated with in utero exposure to metformin or metformin and insulin
A single-center, case-control study of patients who were hospitalized with COVID-19 found a link between elevated levels of IL-6, IL-8, and interferon-γ-induced protein 10 and mortality risk, regardless of whether patients had type 2 diabetes.
Continuous glucose monitoring (CGM) was associated with improved HbA1c levels among adolescents and young adults in one trial and less hypoglycemia among older adults in another.